Nova Biomedical bolsters its cell line development platform by integrating NanoCellect’s microfluidic cell sorting assets
Executive summary: Nova Biomedical announced on July 24, 2026 that it has acquired certain assets from NanoCellect, a provider of microfluidic cell sorting technology. The acquisition expands Nova Biomedical’s capabilities in cell line development, potentially reducing development timelines and costs for therapeutic cell lines and strengthening its offering in the bioprocessing sector.
Who is involved: Nova Biomedical (Waltham, MA) and NanoCellect (microfluidic cell sorting provider); the transaction involves specific assets of NanoCellect.
Likely next: Integration of NanoCellect’s sorting technology into Nova Biomedical’s product lineup, with a potential launch of an integrated workflow solution later in 2026 and ongoing collaboration between the teams.
Nova Biomedical’s acquisition of select NanoCellect assets adds microfluidic cell sorting to its portfolio, enhancing the company’s ability to offer integrated workflows for cell line development. The move addresses a growing demand for faster, more efficient therapeutic cell line generation in the bioprocessing market. By bringing in NanoCellect’s technology, Nova Biomedical strengthens its competitive position against established players in the cell analysis space.
Timeline
- — Nova Biomedical Advances Integrated Cell Line Development Workflows: NanoCellect products are now part of Nova Biomedical (PR Newswire)
Analysis — what this means
Sectors affected
- Cell line development
- Microfluidic cell sorting
- Bioprocessing equipment
Historical parallels
- Danaher’s acquisition of Pall Corporation (2015)
- Thermo Fisher’s acquisition of Patheon (2017)
Key entities
Sources
- Nova Biomedical Advances Integrated Cell Line Development Workflows: NanoCellect products are now part of Nova Biomedical — PR Newswire